Smart Healthcare

Itinai.com biomedical laboratory close up still scene close u e4996bf4 1113 41b3 8fdd 0d1e6c918068 1
Itinai.com biomedical laboratory close up still scene close u e4996bf4 1113 41b3 8fdd 0d1e6c918068 1

Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease

“`html

Study Summary

Patients with nonalcoholic fatty liver disease (NAFLD) are at higher risk of cardiac events. This study aimed to determine if noninvasive liver fibrosis scores can predict cardiac events in NAFLD patients.

Methods

  • 4071 NAFLD patients were assessed using ultrasonography.
  • Liver fibrosis was categorized into three groups based on the Fibrosis-4 (FIB4) index and NAFLD fibrosis score (NFS).
  • The primary outcome was major adverse cardiac events (MACE), including cardiac death, nonfatal myocardial infarction, and coronary artery disease revascularization.

Results

  • During a 6.6-year follow-up, 179 patients (4.4%) experienced MACE.
  • Kaplan-Meier analysis showed a progressive increase in MACE with higher FIB4 index and NFS.
  • Higher FIB4 index and NFS were associated with increased MACE risk.

Conclusions

The study concluded that FIB4 index and NFS are linked to the likelihood of MACE in NAFLD patients.

Clinical Trials

The study was approved by the ethics review board of Ogaki Municipal Hospital (approval number: 20221124-12, registration date: November 28th, 2022). More information

“`

Full Clinical Trial Report Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease: https://pubmed.ncbi.nlm.nih.gov/38664121/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1B1L42DK3a-JWCV4P_PtHHBmWjwBLFNcDXsYJkbqjQD0Ca7UQh&fc=None&ff=20240426043029&v=2.18.0.post9+e462414

Dr M. Trenton

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research